Janus Henderson Group
ELEV

Janus Henderson Group’s Elevation Oncology ELEV Stock Holding History

Janus Henderson Group’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-179,080
Closed -$250K – 2562
2022
Q2 		$250K Sell
179,080
-930,732
-84% -$2.34M ﹤0.01% 2193
2022
Q1 		$2.8M Sell
1,109,812
-29,438
-3% -$118K ﹤0.01% 1137
2021
Q4 		$6.85M Sell
1,139,250
-80,955
-7% -$559K ﹤0.01% 991
2021
Q3 		$9.38M Buy
1,220,205
+188,517
+18% +$2.04M ﹤0.01% 920
2021
Q2 		$13.6M Buy
+1,031,688
New +$12.8M 0.01% 871

Other funds holding ELEV

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group's ELEV Position: Q3 2022 in Review

Janus Henderson Group sold out of Elevation Oncology (ELEV) in Q3 2022, closing a stake of 179,080 shares — an estimated $250K sold.

Janus Henderson Group first reported a position in ELEV in Q2 2021 and held it in 5 quarters. The position peaked at $13.6M in Q2 2021. 25 funds tracked by Wall St. Rank hold ELEV as of Q3 2022.

  • Janus Henderson Group reported no remaining Elevation Oncology position as of Q3 2022 after selling out during the quarter.
  • Janus Henderson Group sold 179,080 Elevation Oncology shares in Q3 2022, an estimated $250K.
  • Janus Henderson Group first reported a position in Elevation Oncology in Q2 2021 and held it in 5 quarters.
  • Janus Henderson Group's Elevation Oncology position peaked at $13.6M in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2022.

Based on Janus Henderson Group's 13F filing for Q3 2022, filed 14 Nov 2022.